CNC Quote, Financials, Valuation and Earnings

Elevance Health has a net margin of 2.81% compared to Centene's net margin of 4.47%. Centene's return on equity of 12.65% beat Elevance Health's return on equity of 14.03%.

Centene has a consensus price target of $54.74, signalling upside risk potential of 79.99%. On the other hand Elevance Health has an analysts' consensus of $474.91 which suggests that it could grow by 37.84%. Given that Centene has higher upside potential than Elevance Health, analysts believe Centene is more attractive than Elevance Health.

Centene has a beta of 0.439, which suggesting that the stock is 56.078% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.515%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.94% to investors and pays a quarterly dividend of $1.71 per share. Centene pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $46.6B, which are smaller than Elevance Health quarterly revenues of $48.9B. Centene's net income of $1.3B is lower than Elevance Health's net income of $2.2B. Notably, Centene's price-to-earnings ratio is 4.53x while Elevance Health's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.09x versus 0.43x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare has a net margin of 2.81% compared to Centene's net margin of 2.67%. Centene's return on equity of 12.65% beat Molina Healthcare's return on equity of 25.66%.

Centene has a consensus price target of $54.74, signalling upside risk potential of 79.99%. On the other hand Molina Healthcare has an analysts' consensus of $310.22 which suggests that it could grow by 43.58%. Given that Centene has higher upside potential than Molina Healthcare, analysts believe Centene is more attractive than Molina Healthcare.

Centene has a beta of 0.439, which suggesting that the stock is 56.078% less volatile than S&P 500. In comparison Molina Healthcare has a beta of 0.551, suggesting its less volatile than the S&P 500 by 44.891%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Molina Healthcare pays out -- of its earnings as a dividend.

Centene quarterly revenues are $46.6B, which are larger than Molina Healthcare quarterly revenues of $11.1B. Centene's net income of $1.3B is higher than Molina Healthcare's net income of $298M. Notably, Centene's price-to-earnings ratio is 4.53x while Molina Healthcare's PE ratio is 10.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.09x versus 0.29x for Molina Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of 2.81% compared to Centene's net margin of 9.04%. Centene's return on equity of 12.65% beat Oscar Health's return on equity of 10.83%.

Centene has a consensus price target of $54.74, signalling upside risk potential of 79.99%. On the other hand Oscar Health has an analysts' consensus of $14.99 which suggests that it could fall by -2.32%. Given that Centene has higher upside potential than Oscar Health, analysts believe Centene is more attractive than Oscar Health.

Centene has a beta of 0.439, which suggesting that the stock is 56.078% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Centene quarterly revenues are $46.6B, which are larger than Oscar Health quarterly revenues of $3B. Centene's net income of $1.3B is higher than Oscar Health's net income of $275.3M. Notably, Centene's price-to-earnings ratio is 4.53x while Oscar Health's PE ratio is 54.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.09x versus 0.42x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 2.81% compared to Centene's net margin of 5.74%. Centene's return on equity of 12.65% beat UnitedHealth Group's return on equity of 21.74%.

Centene has a consensus price target of $54.74, signalling upside risk potential of 79.99%. On the other hand UnitedHealth Group has an analysts' consensus of $380.75 which suggests that it could grow by 30.18%. Given that Centene has higher upside potential than UnitedHealth Group, analysts believe Centene is more attractive than UnitedHealth Group.

Centene has a beta of 0.439, which suggesting that the stock is 56.078% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.449, suggesting its less volatile than the S&P 500 by 55.115%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.91% to investors and pays a quarterly dividend of $2.21 per share. Centene pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $46.6B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Centene's net income of $1.3B is lower than UnitedHealth Group's net income of $6.3B. Notably, Centene's price-to-earnings ratio is 4.53x while UnitedHealth Group's PE ratio is 12.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.09x versus 0.66x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.